Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update Achieves Robust ...

Achieves Robust Financial Performance with 74% Gross Margin and Strategic Public Offering, Bolstering Resources for Continued Growth and Innovation.Elevai Enfinity Clinical Trials Showcase Breakthroug ...

Mississauga, Ontario Thursday, November 14, 2024, 09:00 Hrs [IST] ...

Ojjaara is an once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor. The approval of Ojjaara by Health ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

Keros Therapeutics (KROS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

Analysis in melanoma cells reveals that proteolytic maturation of Activin-A is regulated by the connectivity of disulfide bonds near the furin cleavage site and stimulates tumor growth only if ...

LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...